|Cell Line Name:||COR-L23/R23-|
|Keywords:||Human Caucasian lung large cell carcinoma,drug-resistant revertant|
|Cell Line Description:||The revertant lung cancer cell line COR-L23/R23- was generated by growing the doxorubicin-selected, resistant variant COR-L23/R (ECACC catalogue no. 96042339) without drug exposure for 24-28 weeks. The cell line, also known as COR-L23/Rev, overexpresses multidrug resistance -associated protein (MRP), but to a lesser extent than the parent line. It was shown that the cell line has the ability to recover quickly, similar levels of MRP expression and resistance as COR-L23/R after a transient exposure to the MDR-drugs doxorubicin and vincristine.|
|Subculture Routine:||Split sub-confluent cultures (70-80%) 1:3 to 1:6 using 0.25% trypsin or trypsin/EDTA; 5% CO2; 37°C|
|Culture Medium:||RPMI 1640 +2mM Glutamine + 10% Foetal Bovine Serum (FBS).|
|Depositor:||Dr. P. Twentyman, Dr. K. Wright, UKCCR, Lincolns Inn Field, London|
|References:||Eur J Cancer 1996; 32A:2136|
|Additional Bibliography:||Not specified|
|Patents:||None specified by Depositor|
|Research Council Deposit:||Yes|
The Culture Collections represent deposits of cultures from world-wide sources. While every effort is made to ensure details distributed by Culture Collections are accurate, Culture Collections cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and Culture Collections does not guarantee the passage number stated will be the passage number received by the customer.
Cultures supplied by Culture Collections are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.
Please confirm your country of origin from the list below.